Iron status among HIV-infected adults during the first year of antiretroviral therapy in Tanzania.
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
20
07
2022
accepted:
15
08
2022
pmc-release:
01
04
2024
medline:
12
4
2023
pubmed:
9
9
2022
entrez:
8
9
2022
Statut:
ppublish
Résumé
The influence of inflammation on iron status among people living with HIV (PLWHIV) has not been well explored. We evaluated the trajectory of iron status among PLWHIV during the first year of highly active antiretroviral therapy (HAART), compared alternative approaches for inflammation correction, and assessed the associations of iron status with HIV-1 viral load and anthropometric outcomes. We conducted a secondary analysis of data from a randomized trial among 400 adults initiating HAART in Tanzania. Ferritin and C-reactive protein (CRP) were measured at baseline, 1, 6 or 12 months. Ferritin was considered in four ways: unadjusted, and adjusted for inflammation using higher cut-off (HC), Thurnham-corrected (TC) and regression-corrected (RC) approaches. For unadjusted, TC and RC ferritin, iron deficiency (ID) was defined using ferritin < 15 μg/L and elevated iron status was defined using ferritin > 150 μg/L among females and > 200 μg/L among males. For HC ferritin, elevated iron status was defined based on serum ferritin > 500 μg/L, while ID was defined using ferritin < 70 μg/L in the presence of inflammation and < 15 μg/L in the absence of inflammation. Regression models evaluated the trajectory of ferritin concentration across categories of baseline characteristics, and assessed the association of iron status with viral and anthropometric outcomes. The prevalence of iron deficiency at HAART initiation was 9% for unadjusted, 17% for HC, 12% for TC and 22% for RC ferritin. The prevalence of elevated iron status was 42% for unadjusted, 18% for HC, 31% for TC, and 15% for RC ferritin. The prevalence of iron deficiency for all three methods increased during the first year of HAART, while the prevalence of elevated iron status decreased. Baseline elevated iron status defined using HC ferritin was associated with a greater risk of HIV-1 viral load > 1000 copies/mL [relative risk (RR) = 4.29, 95% CI: 1.38-13.3] and incidence of being underweight [body mass index (BMI) < 18.5 kg/m Whether and how inflammation correction is done influences findings of studies of iron status among PLWHIV.
Sections du résumé
BACKGROUND
The influence of inflammation on iron status among people living with HIV (PLWHIV) has not been well explored. We evaluated the trajectory of iron status among PLWHIV during the first year of highly active antiretroviral therapy (HAART), compared alternative approaches for inflammation correction, and assessed the associations of iron status with HIV-1 viral load and anthropometric outcomes.
METHODS
We conducted a secondary analysis of data from a randomized trial among 400 adults initiating HAART in Tanzania. Ferritin and C-reactive protein (CRP) were measured at baseline, 1, 6 or 12 months. Ferritin was considered in four ways: unadjusted, and adjusted for inflammation using higher cut-off (HC), Thurnham-corrected (TC) and regression-corrected (RC) approaches. For unadjusted, TC and RC ferritin, iron deficiency (ID) was defined using ferritin < 15 μg/L and elevated iron status was defined using ferritin > 150 μg/L among females and > 200 μg/L among males. For HC ferritin, elevated iron status was defined based on serum ferritin > 500 μg/L, while ID was defined using ferritin < 70 μg/L in the presence of inflammation and < 15 μg/L in the absence of inflammation. Regression models evaluated the trajectory of ferritin concentration across categories of baseline characteristics, and assessed the association of iron status with viral and anthropometric outcomes.
RESULTS
The prevalence of iron deficiency at HAART initiation was 9% for unadjusted, 17% for HC, 12% for TC and 22% for RC ferritin. The prevalence of elevated iron status was 42% for unadjusted, 18% for HC, 31% for TC, and 15% for RC ferritin. The prevalence of iron deficiency for all three methods increased during the first year of HAART, while the prevalence of elevated iron status decreased. Baseline elevated iron status defined using HC ferritin was associated with a greater risk of HIV-1 viral load > 1000 copies/mL [relative risk (RR) = 4.29, 95% CI: 1.38-13.3] and incidence of being underweight [body mass index (BMI) < 18.5 kg/m
CONCLUSIONS
Whether and how inflammation correction is done influences findings of studies of iron status among PLWHIV.
Identifiants
pubmed: 36075691
doi: 10.1111/hiv.13396
pmc: PMC9992443
mid: NIHMS1830919
doi:
Substances chimiques
Iron
E1UOL152H7
Biomarkers
0
Ferritins
9007-73-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
398-410Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK098075
Pays : United States
Informations de copyright
© 2022 British HIV Association.
Références
Health Aff (Millwood). 2019 Jul;38(7):1163-1172
pubmed: 31260344
Exp Clin Endocrinol Diabetes. 1998;106 Suppl 2:10-3
pubmed: 9792475
J Nutr. 2020 Sep 1;150(9):2375-2382
pubmed: 32621487
Am J Epidemiol. 2012 Feb 1;175(3):210-7
pubmed: 22262640
Br J Nutr. 2009 Aug;102(4):605-9
pubmed: 19173765
AIDS Care. 2017 Feb;29(2):156-167
pubmed: 27454239
Clin Infect Dis. 2017 Jan 15;64(2):124-131
pubmed: 27737952
AIDS Res Hum Retroviruses. 2015 Mar;31(3):305-12
pubmed: 25291189
BMC Infect Dis. 2013 Jan 29;13:48
pubmed: 23360117
Am J Clin Nutr. 2017 Jul;106(Suppl 1):359S-371S
pubmed: 28615259
Anesth Analg. 2020 Feb;130(2):542-546
pubmed: 31725019
HIV Med. 2007 Sep;8(6):388-95
pubmed: 17661847
PLoS One. 2013 Nov 11;8(11):e79904
pubmed: 24244576
Lancet HIV. 2020 Jul;7(7):e463-e471
pubmed: 32621874
PLoS Med. 2008 Oct 21;5(10):e203
pubmed: 18942885
Clin Infect Dis. 2013 Dec;57(11):1626-34
pubmed: 23956164
Mil Med. 2017 Mar;182(3):e1810-e1818
pubmed: 28290964
Am J Epidemiol. 2005 Aug 1;162(3):199-200
pubmed: 15987728
Nutrients. 2018 Apr 12;10(4):
pubmed: 29649107
J Nutr. 2018 Jun 1;148(suppl_1):1001S-1067S
pubmed: 29878148
Blood. 2019 Jan 3;133(1):40-50
pubmed: 30401705
BMC Infect Dis. 2014 Dec 21;14:3860
pubmed: 25528467
J Nutr. 2012 Feb;142(2):350-7
pubmed: 22190024
AIDS. 2004 Dec 3;18(18):2434-7
pubmed: 15622323
BMC Pediatr. 2015 Oct 19;15:164
pubmed: 26482352
J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):219-25
pubmed: 16186741
Am J Trop Med Hyg. 2019 Jun;100(6):1512-1520
pubmed: 31017077
Biochim Biophys Acta. 2012 Mar;1820(3):403-10
pubmed: 21855608
AIDS. 1999 Feb 25;13(3):375-80
pubmed: 10199228
Antivir Ther. 2012;17(5):915-9
pubmed: 22436412
Am J Trop Med Hyg. 2018 Nov;99(5):1336-1341
pubmed: 30226135
PLoS One. 2012;7(3):e24243
pubmed: 22448211
AIDS. 2005 Mar 4;19(4):399-406
pubmed: 15750393
Adv Nutr. 2020 Sep 1;11(5):1334-1363
pubmed: 32383731
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
J Infect. 1999 Jan;38(1):18-21
pubmed: 10090500
J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):298-303
pubmed: 17414930
PLoS One. 2012;7(5):e37350
pubmed: 22606361
J Acquir Immune Defic Syndr. 2004 May 1;36(1):637-8
pubmed: 15097308
Lancet Infect Dis. 2017 Dec;17(12):1285-1292
pubmed: 28847636
Curr Opin Clin Nutr Metab Care. 2016 Nov;19(6):458-463
pubmed: 27583708
Am J Clin Nutr. 2010 Sep;92(3):546-55
pubmed: 20610634